• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Digital Therapeutics Prescription vs. Non-Prescription Pathways

Press Release

Digital therapeutic (DTx) products have the ability to reach patients and caregivers through a variety of patient access pathways. This results in a diverse landscape of possible DTx market access models. In the past, DTx prescription products have been viewed as the only gated patient access path; however, that is not the case. Nearly all patient access to DTx today—including prescription and non-prescription products—involves vetting by a third- party to ensure the right patients have access to the right products.

Product authorization and patient access pathways may differ based on local or national DTx regulatory, Health Technology Assessment (HTA), or payor requirements.

© 2023 MJH Life Sciences

All rights reserved.